<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="208">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 08, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01662349</url>
  </required_header>
  <id_info>
    <org_study_id>MOE - 121</org_study_id>
    <nct_id>NCT01662349</nct_id>
  </id_info>
  <brief_title>Safety Study of Plasma Treatment System to Treat Back Acne</brief_title>
  <official_title>A Single Center, Pilot Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of the Plasma Treatment System in Treating Back Acne</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Moe Medical Devices</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Moe Medical Devices</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety of treating human skin with atmospheric
      plasma and get an initial evaluation of the efficacy of this treatment for acne.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2012</start_date>
  <primary_completion_date type="Anticipated">June 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change in number of reported adverse events</measure>
    <time_frame>Change from Baseline to 1 month post-treatment</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Acne Vulgaris</condition>
  <arm_group>
    <arm_group_label>Plasma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Plasma applied to back for up to 20 minutes, twice/week for 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MOE Antimicrobial Plasma Treatment System</intervention_name>
    <description>Plasma applied to back for up to 20 minutes, twice/week for 4 weeks</description>
    <arm_group_label>Plasma</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males and non-pregnant, non-nursing females age 18-40 years old.

          2. Presence of clinically-evident back acne.

          3. Minimum of 20 non-inflammatory lesions (open and closed comedones)

          4. Minimum of 30 total lesions (sum of inflammatory and non-inflammatory)

          5. Subject must have measurable sebum production.

          6. Subjects must be in generally good health.

          7. Must be able and willing to comply with the requirements of the protocol.

        Exclusion Criteria:

          1. Any nodulo-cystic lesions at Baseline

          2. Pregnancy or breast feeding

          3. Use of acne devices or systemic therapy with antibiotics within four months prior to
             start and throughout the duration of the study

          4. Intake of any oral retinoids within four months prior to study start and throughout
             the duration of the study

          5. Topical use of topical retinoids within two weeks prior to study start and throughout
             the duration of the study

          6. Topical use of antibiotics, steroids and/or other non-retinoid topical acne products
             within two weeks prior to study start and throughout the duration of the study

          7. Use of an experimental drug or device within 30 days prior to study start;

          8. Intake of hormonal therapy within 3 months prior to study start

          9. Use of topical products on the back containing glycolic or other acids, masks, washes
             or soaps containing benzoyl peroxide or salicylic acid, non mild cleansers or
             moisturizers containing retinol, salicylic or α- or β-hydroxy acids.

         10. Concomitant use of mega-doses of certain vitamins, such as vitamin D (&gt;2000IU QD)
             vitamin B12, haloperidol, halogens such as iodide and bromide, lithium, hydantoin and
             phenobarbital.

         11. Procedures on the skin of the back such as chemical or laser peel, microdermabrasion,
             photodynamic therapy) within the past 2 weeks or during the study.

         12. History or evidence of other skin conditions or diseases that may require concurrent
             therapy or may interfere with the evaluation of the study medication

         13. Any significant medical conditions that could confound the interpretation of the
             study results.

         14. History of/or current skin cancer cancer

         15. Use of tanning booths, sun lamps within the past 2 weeks or during the study

         16. Any metallic implants or prostheses in the vicinity of the treatment site (such as
             shoulders, back, spine, pacemakers, etc.).

         17. Any known photosensitivity disorders felt by the investigators to preclude safe
             inclusion in the study.

         18. History of significant post-inflammatory hyperpigmentation at the sites of acne
             lesions.

         19. History of or is currently immunocompromised.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexandra B. Kimball, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Partners Healthcare System</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alexandra B. Kimball, MD</last_name>
    <phone>617-726-5066</phone>
    <email>harvardskinstudies@partners.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinical Unit for Research Trials and Outcomes in Skin (CURTIS)</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Alexandra B. Kimball, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <lastchanged_date>September 11, 2012</lastchanged_date>
  <firstreceived_date>August 2, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anti-Infective Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
